Life
U.K. to Review Cost-Effectiveness of New Alzheimer's Treatments
The U.K. government is set to reassess the cost-effectiveness of two Alzheimer's drugs following appeals from manufacturers, which may impact healthcare funding.
Editorial Staff
1 min read
The U.K. government has announced a review of the cost-effectiveness of two new Alzheimer's treatments, responding to successful appeals from drugmakers.
This reassessment is scheduled for March 20, 2026, and could have significant implications for healthcare funding and resource allocation within the National Health Service.
The outcome of this review will likely influence the availability and pricing of these drugs, as well as the overall strategy for Alzheimer's treatment in the U.K.